Intervacc Ab

Ultupharma Ab

Alfa Laval Corporation Ab

Biostapro Ab

Guss, Bengt

Flock, Jan-ingmar

Bergman, Rune

Flock, Margareta

Janzon, Kenneth

Jacobsson, Karin

Frykberg, Lars

Bengt Guss

Jan-Ingmar Flock

Lars Frykberg

Margareta Flock

Jolanta Levenfors

Anders Broberg

Joakim Bjerketorp

Bo Öberg

Christina Nord

Martin K Lindberg

Karl Olov Zachrisson

Magnus Hook

Christer Signas

Karin Jacobsson

Hans Jonsson

Lech Switalski

Joseph Patti

Kenneth Janzon

Rune Bergman

Martin Nilsson

Bo Oberg

The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may be cyclic peptides, sometimes depsipeptides, or non-ring-closed peptides, as defined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.

Peptide compounds

The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible toinfection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.

Vaccine againstinfection

The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.

Method of treating bacterial infections

The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.

The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both ofsubsp.and subsp.and use thereof for immunization of non-human mammals againstsubsp.and/or subsp.. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.

Immunizing composition

An antigenic composition comprises several antigenic components derived from antigens ofsubsp.or subsp., wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals againstsubsp.and/or subsp.. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.

Vaccine against streptococcal infections based on recombinant proteins

An antigenic composition comprises several antigenic components derived from antigens ofsubsp.or subsp., wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals againstsubsp.and/or subsp.. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.

The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both ofsubsp.and subsp.and use thereof for immunization of non-human mammals againstsubsp.and/or subsp.. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.

[object Object]

A new fibrinogen binding protein or polypeptide originating from coagulase negativebiotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negativeand a vaccine composition, comprising the protein or DNA.

Antibodies to a fibrinogen binding protein of staphylococcus epidermidis

The present invention relates to a new recombinant DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein, or polypeptide, having collagen binding properties.

Collagen binding protein as well as its preparation

Growing community of inventors

Uppsala, Sweden

Bengt Guss